Abstract
A growing body of evidence has shown that critical illness and associated treatments can lead to de novo neurological degradation manifesting as delirium or acute brain dysfunction. Many survivors further suffer from long-term cognitive impairment (LTCI), months to years after their critical illness, affecting their functional quality of life. Recent data have demonstrated that delirium is an independent risk factor for increased morbidity and mortality in the critically ill and may also predispose patients to long-term cognitive impairment. Delirium, therefore, may represent a critical point for intervention and treatment in critically ill patients. The pathogenesis of delirium is multifactorial and is considered to be related to several physiological and possibly iatrogenic processes. Due to its complexity, the optimum pharmacological treatment by which to manage delirium is not fully understood; however, recent investigations have proposed several plausible protocols. In this review, we examine evidence pertaining to the pharmacological treatment of delirium in the context of acute critical illness.
Keywords: Delirium, psychosis, acute critical illness, therapy, antipsychotics, side effects
Current Drug Therapy
Title: The Pharmacological Management of Delirium in Critical Illness
Volume: 3 Issue: 2
Author(s): Alessandro Morandi, Max L. Gunther, E. Wesley Ely and Pratik Pandharipande
Affiliation:
Keywords: Delirium, psychosis, acute critical illness, therapy, antipsychotics, side effects
Abstract: A growing body of evidence has shown that critical illness and associated treatments can lead to de novo neurological degradation manifesting as delirium or acute brain dysfunction. Many survivors further suffer from long-term cognitive impairment (LTCI), months to years after their critical illness, affecting their functional quality of life. Recent data have demonstrated that delirium is an independent risk factor for increased morbidity and mortality in the critically ill and may also predispose patients to long-term cognitive impairment. Delirium, therefore, may represent a critical point for intervention and treatment in critically ill patients. The pathogenesis of delirium is multifactorial and is considered to be related to several physiological and possibly iatrogenic processes. Due to its complexity, the optimum pharmacological treatment by which to manage delirium is not fully understood; however, recent investigations have proposed several plausible protocols. In this review, we examine evidence pertaining to the pharmacological treatment of delirium in the context of acute critical illness.
Export Options
About this article
Cite this article as:
Morandi Alessandro, Gunther L. Max, Ely Wesley E. and Pandharipande Pratik, The Pharmacological Management of Delirium in Critical Illness, Current Drug Therapy 2008; 3 (2) . https://dx.doi.org/10.2174/157488508784221262
DOI https://dx.doi.org/10.2174/157488508784221262 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Using Structural and Mechanistic Information to Design Novel Inhibitors/Substrates of P-Glycoprotein
Current Topics in Medicinal Chemistry Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Emerging Antimicrobial Applications of Nitric Oxide (NO) and NO-Releasing Materials
Anti-Infective Agents in Medicinal Chemistry The Use of Novel Oral Anticoagulants in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Women and Schizophrenia: Sex-Based Pharmacotherapy
Current Psychiatry Reviews Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Ethyl Pyruvate: A Novel Treatment for Sepsis
Current Drug Targets Clozapine Safety, 35 Years Later
Current Drug Safety Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets Vicious Cycles Within the Neuropathophysiologic Mechanisms of Alzheimers Disease
Current Alzheimer Research